EP1175246A4 - Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductase - Google Patents
Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductaseInfo
- Publication number
- EP1175246A4 EP1175246A4 EP00916511A EP00916511A EP1175246A4 EP 1175246 A4 EP1175246 A4 EP 1175246A4 EP 00916511 A EP00916511 A EP 00916511A EP 00916511 A EP00916511 A EP 00916511A EP 1175246 A4 EP1175246 A4 EP 1175246A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- upregulation
- hmg
- nitric oxide
- endothelial cell
- coa reductase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27344599A | 1999-03-19 | 1999-03-19 | |
US273445 | 1999-03-19 | ||
PCT/US2000/007221 WO2000056403A1 (fr) | 1999-03-19 | 2000-03-17 | Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1175246A1 EP1175246A1 (fr) | 2002-01-30 |
EP1175246A4 true EP1175246A4 (fr) | 2004-12-15 |
Family
ID=23043964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00916511A Withdrawn EP1175246A4 (fr) | 1999-03-19 | 2000-03-17 | Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1175246A4 (fr) |
JP (1) | JP2003511347A (fr) |
AU (1) | AU3760300A (fr) |
CA (1) | CA2368187A1 (fr) |
WO (1) | WO2000056403A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239172B1 (en) | 1997-04-10 | 2001-05-29 | Nitrosystems, Inc. | Formulations for treating disease and methods of using same |
US5968983A (en) | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
US6425881B1 (en) | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
AU4013900A (en) | 1999-03-19 | 2000-10-09 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
WO2002062300A2 (fr) * | 2001-02-07 | 2002-08-15 | The Mclean Hospital Corporation | Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs |
DE10257360A1 (de) * | 2002-12-09 | 2004-07-08 | Fresenius Kabi Deutschland Gmbh | Gastro-intestinal verabreichbare Formulierung und deren Verwendung |
US9345671B2 (en) | 2003-04-28 | 2016-05-24 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
WO2004096276A1 (fr) | 2003-04-28 | 2004-11-11 | Sankyo Company, Limited | Composition activant l'aptitude a consommer du sucre |
DE10330768A1 (de) * | 2003-07-07 | 2005-02-24 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung |
CA2545584C (fr) | 2003-11-17 | 2012-10-23 | Biomarin Pharmaceutical Inc. | Methodes et compositions destinees au traitement de troubles metaboliques |
EP1729761A4 (fr) * | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | Traitement de cadasil avec des inhibiteurs de la cholinesterase |
TW200612896A (en) * | 2004-09-21 | 2006-05-01 | Sankyo Co | Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione |
JP4949661B2 (ja) * | 2004-09-21 | 2012-06-13 | 第一三共株式会社 | HMG−CoAリダクターゼ阻害剤とグルタチオンを含有する医薬組成物 |
US7893050B2 (en) | 2005-10-26 | 2011-02-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
WO2008036846A2 (fr) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Modulation induite par hmg-coa-réductase de la neurogenèse |
US20100174075A1 (en) * | 2007-06-25 | 2010-07-08 | Nicox S.A. | Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US20200253976A1 (en) * | 2017-09-28 | 2020-08-13 | University Of Massachusetts | Endothelial Facilitation in Neurodegerative Diseases by Cerebral Blood Flow Enhancement |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2020212948A1 (fr) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Procédés pour traiter les troubles neurocognitifs, la douleur chronique, et pour réduire l'inflammation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671171A1 (fr) * | 1994-01-18 | 1995-09-13 | Bristol-Myers Squibb Company | Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques |
WO1999018952A1 (fr) * | 1997-10-14 | 1999-04-22 | Brigham & Women's Hospital, Inc. | REGULATION POSITIVE DE L'OXYDE NITRIQUE SYNTHASE DE CELLULES ENDOTHELIALES DE TYPE III PAR DES INHIBITEURS DE LA HMG-CoA REDUCTASE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
-
2000
- 2000-03-17 WO PCT/US2000/007221 patent/WO2000056403A1/fr not_active Application Discontinuation
- 2000-03-17 CA CA002368187A patent/CA2368187A1/fr not_active Abandoned
- 2000-03-17 AU AU37603/00A patent/AU3760300A/en not_active Abandoned
- 2000-03-17 EP EP00916511A patent/EP1175246A4/fr not_active Withdrawn
- 2000-03-17 JP JP2000606302A patent/JP2003511347A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671171A1 (fr) * | 1994-01-18 | 1995-09-13 | Bristol-Myers Squibb Company | Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques |
WO1999018952A1 (fr) * | 1997-10-14 | 1999-04-22 | Brigham & Women's Hospital, Inc. | REGULATION POSITIVE DE L'OXYDE NITRIQUE SYNTHASE DE CELLULES ENDOTHELIALES DE TYPE III PAR DES INHIBITEURS DE LA HMG-CoA REDUCTASE |
Non-Patent Citations (4)
Title |
---|
BOEGER RAINER H ET AL: "Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin", CIRCULATION, vol. 96, no. 4, 1997, pages 1282 - 1290, XP002302014, ISSN: 0009-7322 * |
ENDRES ET AL: "stroke protection by HMG-CoA reductase inhibitors mediated by endothelial nitric oxide synthase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 15, 1 July 1998 (1998-07-01), pages 8880 - 8885, XP002091890, ISSN: 0027-8424 * |
LAUFS ET AL: "inhibition of HMG-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 50, 12 December 1997 (1997-12-12), pages 31725 - 31729, XP002091893, ISSN: 0021-9258 * |
See also references of WO0056403A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000056403A1 (fr) | 2000-09-28 |
CA2368187A1 (fr) | 2000-09-28 |
JP2003511347A (ja) | 2003-03-25 |
EP1175246A1 (fr) | 2002-01-30 |
AU3760300A (en) | 2000-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1175246A4 (fr) | Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductase | |
AU3107599A (en) | Upregulation of type iii endothelial cell nitric oxide synthase by (rho) gtpase function inhibitors | |
IL145364A0 (en) | Aminopyrimidines as sorbitol dehydrogenase inhibitors | |
PL359820A1 (en) | Hmg-coa reductase inhibitors and method | |
HK1050521A1 (en) | Amidino compounds useful as nitric oxide synthase inhibitors | |
GB0031179D0 (en) | Nitric oxide synthase inhibitors | |
AU2001293373A1 (en) | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | |
AU2001266696A1 (en) | Compounds for targeting endothelial cells | |
AU2002222252A1 (en) | Nitric oxide synthase inhibitor phosphate salt | |
NO20033635D0 (no) | Pyrimidinderivater for inhibering av celle-formering | |
HUP0401052A3 (en) | Dna-pk inhibitors | |
AU5170900A (en) | Cell proliferation inhibitors | |
AU6909300A (en) | Substituted ureas as cell adhesion inhibitors | |
EP1684754A4 (fr) | Inhibiteurs de la reductase hmg-coa et procede associe | |
PL355099A1 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors | |
AU6381701A (en) | Bisamidino compounds as nhe-3 inhibitors | |
EP1286702A4 (fr) | Inhibiteurs de la hmg coa reductase pour favoriser l'angiogenese | |
HK1047434B (zh) | 噻吩並嘧啶化合物 | |
AU2003272719A1 (en) | Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents | |
AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
AU2003302588A1 (en) | Phosphodiesterase 10a inhibitors | |
MXPA03002858A (es) | Forma amorfa del inhibidor del ciclo celular. | |
AU2001282746A1 (en) | Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors | |
AU2002224550A1 (en) | Corrosion inhibitors | |
PL336853A1 (en) | Derivatives of amidine as inhibitors of nitrogen oxide synthase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011017 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOSKOWITZ, MICHAEL, A. Inventor name: ENDRES, MATTHIAS Inventor name: LAUFS, ULRICH Inventor name: LIAO, JAMES, K. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE GENERAL HOSPITAL CORPORATION Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041104 |
|
17Q | First examination report despatched |
Effective date: 20061011 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061003 |